According to a new report published by KBV Research, the Global Human Milk Oligosaccharides (HMO) Market is expected to reach USD 891.2 Million by 2033, growing at a CAGR of 11.3% during the forecast period.
The Global Human Milk Oligosaccharides Market is experiencing robust growth driven by increasing awareness regarding infant nutrition, expanding applications in gut health and immune support, and growing scientific validation of HMO functionality. Human Milk Oligosaccharides, recognized as one of the most important bioactive components in human breast milk, have become a key focus area within the nutrition and health industries. Advances in microbial fermentation, enzymatic synthesis, and biotechnology have enabled large-scale commercial production of HMOs, facilitating their incorporation into infant formula, dietary supplements, functional foods, and pharmaceutical products. Manufacturers continue to invest in advanced production technologies, regulatory approvals, and product innovation to expand the commercialization of HMOs globally.
Today, HMOs have evolved from niche research ingredients into mainstream nutritional components utilized across infant nutrition and emerging adult health applications. The market continues to benefit from technological advancements in microbial fermentation, increasing clinical validation of health benefits, growing regulatory support, and expanding demand for premium nutritional products. Precision fermentation and advanced biotechnological production methods are transforming large-scale HMO manufacturing, while increasing regulatory approvals are accelerating ingredient commercialization across global markets. Companies are increasingly focusing on diversified HMO portfolios, advanced formulation capabilities, and geographically targeted expansion strategies to strengthen their competitive positions.
The Infant Formula segment is leading the Global Human Milk Oligosaccharides Market by Application in 2025 and would continue to be a dominant segment through 2033, thereby achieving a market value of USD 673.5 Million by 2033. The segment’s growth is driven by increasing demand for advanced infant nutrition products that closely mimic the composition and functional benefits of human breast milk. Infant formula manufacturers are increasingly incorporating HMOs into formulations to support immune system development, improve gut microbiota balance, and enhance overall infant health outcomes. In 2025, Infant Formula accounted for 77.51% of the market revenue share, underscoring its dominant position within the HMO ecosystem.
The 2’FL (2’-Fucosyllactose) segment generated the highest revenue share in the Global Human Milk Oligosaccharides Market by Type in 2025 and is expected to maintain its leadership position throughout the forecast period, reaching a market value of USD 354.1 Million by 2033. The segment’s growth is attributed to its extensive utilization in infant nutrition products and strong scientific validation regarding digestive and immune health benefits. Manufacturers increasingly utilize 2’FL to improve formula functionality, support gut microbiome development, and enhance infant immune system maturation. In 2025, 2’FL accounted for 43.13% of the market revenue share, making it the most widely adopted HMO type globally.
The North America region dominated the Global Human Milk Oligosaccharides Market by Region in 2025 and is expected to remain the leading regional market through 2033, reaching a market value of USD 298.2 Million by 2033. The region’s leadership is supported by strong adoption of premium infant nutrition products, increasing consumer awareness regarding infant health, substantial investments in nutritional science research, and a favorable regulatory environment supporting HMO commercialization. Meanwhile, Asia Pacific is expected to witness the fastest growth during the forecast period, driven by expanding infant nutrition markets, rising disposable incomes, and increasing awareness of advanced nutritional ingredients.
Key companies operating in the market include DSM-Firmenich AG, International Flavors & Fragrances Inc., BASF SE, Abbott Laboratories, Nestlé S.A., FrieslandCampina C.V., Novonesis A/S, Inbiose NV, KYOWA HAKKO BIO Co., Ltd. (Kirin Holdings Co., Ltd.), and ELICITYL S.A.
By Application
By Type
By Geography
Unique Offerings
